Press Releases
Cell Signaling Technology, Inc. and Zeptosens AG enter into Antibody Supply and License Agreement
Beverly, Mass. and Witterswil, Switzerland - April 19, 2004 - Cell Signaling Technology, Inc. (CST) and Zeptosens AG, announced the signing of a supply and license agreement, for the use and resale of certain CST reagents by Zeptosens in conjunction with its ZeptoMARKTM protein microarray platform. These reagents include phospho-specific antibodies to key signaling molecules and important therapeutic targets for pharmaceutical drug discovery such as kinases. Kinases are the primary mediators of signaling, modulating nearly every cellular process by phosphorylating protein substrates to regulate their function. The ZeptoMARKTM CeLyA (Cell Lysate Arrays) in combination with CST’s specific antibodies provides a complete, high performance microarray system for efficient monitoring of protein expression and fast, quantitative protein activation profiling.
“Cell Signaling Technology is excited about the application of our antibody content in the Zeptosens protein microarray platform,” said Christopher Bunker, CST’s Director of Pharma Services. “The planar waveguide technology that underlies ZeptoMARKTM arrays enables ultra-sensitive and highly parallel, quantifiable assays of kinase and pathway activation. These assays will enable more rapid cellular pathway analyses that will facilitate target validation, drug discovery and clinical assays of kinase inhibitor efficacy.”
“With the growing set of premium quality CST’s antibodies validated and used in our ZeptoMARKTM CeLyA protein profiling system and assays, we are now offering a complete analytical solution for the signal transduction research community. Scientists of a broad range of disciplines from pathology to early drug profiling can now benefit from the highest analytical system performance, enabling highly accurate and economical pathway analysis.” stated Peter Oroszlan, Zeptosens’ Director of Business Development.
About Zeptosens
Zeptosens AG develops and commercializes high-performance and high-throughput universal microarray platforms comprising nanotechnology based, high sensitivity microarrays, readout systems and image analysis software for both gene and protein applications for use in life sciences as well as in food and environmental analysis. For more information please visit www.zeptosens.com
About Cell Signaling Technology
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies for kinase and pathway activation measurement. CST’s phospho-specific antibodies are validated on a range of cellular and biochemical assay platforms and are critical reagents used in basic biomedical research, pharmaceutical drug discovery, and clinical pathology. More information on CST can be obtained at the Company’s web site at www.cellsignal.com
For more information, contact:
Dr. Peter Oroszlan
Zeptosens AG
Director, Business Development
phone: +41 (61) 726 8161
e-mail: peter.oroszlan@zeptosens.com
